


AZD8931 STUDY 4

In metastatic breast cancer

A phase II, randomized, double-blind, placebo-controlled, multicenter study in women with hormone receptor positive, endocrine therapy naïve, metastatic breast cancer to compare the efficacy of AZD8931 in combination with anastrozole vs anastrozole plus placebo



Purpose: To determine if the combination of AZD8931 with anastrozole is more effective in treating hormone receptor positive, endocrine therapy naïve, metastatic breast cancer compared to anastrozole alone

Primary endpoint: Progression-free survival

Secondary endpoints: Safety and tolerability, objective tumor response rate, overall survival, duration of response, clinical benefit rate, time to documented disease progression, pharmacokinetics and health-related quality of life

Participating countries: Brazil | Columbia | Czech Republic | Finland | Hungary | Korea | Malaysia | Mexico | Netherlands | Peru | Philippines | Poland | Portugal | South Africa | Taiwan | Ukraine | United Kingdom | United States

AZD8931 is an investigational compound. This information is intended for potential clinical investigators and other interested physicians who may wish to enroll patients in clinical trials.

For more information,
please contact:

Cancer Study Locator service, sponsored by
AstraZeneca at 1-877-400-4656
Or via e-mail at: astrazeneca@emergingmed.com
To find available investigator site details, go to: www.clinicaltrials.gov

AstraZeneca 

AstraZeneca Pharmaceuticals, LP
Wilmington, Delaware
www.astrazeneca.com